Caitlyn Meinzer

Follow

Generating author description...

All published works
Action Title Year Authors
+ Designing a phase‐III time‐to‐event clinical trial using a modified sample size formula and Poisson‐Gamma model for subject accrual that accounts for the lag in site initiation using the <scp>PERT</scp> distribution 2023 Virginia B Shipes
Caitlyn Meinzer
Bethany J. Wolf
Hong Li
Matthew J. Carpenter
Hooman Kamel
Renee Martin
+ PDF Chat Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients 2022 Guangyi Gao
Byron J. Gajewski
Jo Wick
Jonathan Beall
Jeffrey L. Saver
Caitlyn Meinzer
Colin P. Derdeyn
David Fiorella
Tudor Jovin
Pooja Khatri
+ PDF Chat Optimizing a Bayesian Hierarchical Adaptive Platform Trial Design for Stroke Patients 2021 Guangyi Gao
Byron J. Gajewski
Jo Wick
Jonathan Beall
Jeffrey L. Saver
Caitlyn Meinzer
+ PDF Chat Correction to: Two-stage Bayesian hierarchical modeling for blinded and unblinded safety monitoring in randomized clinical trials 2020 Junhao Liu
Jo Wick
Renee Martin
Caitlyn Meinzer
Dooti Roy
Byron Gajewski
+ PDF Chat Two-stage Bayesian hierarchical modeling for blinded and unblinded safety monitoring in randomized clinical trials 2020 Junhao Liu
Jo Wick
Renee Martin
Caitlyn Meinzer
Dooti Roy
Byron Gajewski
+ PDF Chat Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials 2019 Byron J. Gajewski
Caitlyn Meinzer
Scott Berry
Gaylan L. Rockswold
William G. Barsan
Frederick K. Korley
Renee Martin
+ Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints 2019 Zhenning Yu
Viswanathan Ramakrishnan
Caitlyn Meinzer
+ Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints 2019 Zhenning Yu
Viswanathan Ramakrishnan
Caitlyn Meinzer
+ PDF Chat Bayesian dose selection design for a binary outcome using restricted response adaptive randomization 2017 Caitlyn Meinzer
Reneé H. Martin
José I. Suárez
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials 2015 P. Thall
Patricia S. Fox
J. Kyle Wathen
3
+ PDF Chat Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus 2013 Jason T. Connor
Jordan Elm
Kristine Broglio
3
+ PDF Chat Are outcome-adaptive allocation trials ethical? 2015 Spencer Phillips Hey
Jonathan Kimmelman
3
+ PDF Chat Practical Bayesian adaptive randomisation in clinical trials 2007 Peter F. Thall
J. Kyle Wathen
3
+ PDF Chat Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE 2017 Brian M. Alexander
Sujuan Ba
Mitchel S. Berger
Donald A. Berry
Webster K. Cavenee
Susan M. Chang
Timothy F. Cloughesy
Tao Jiang
Mustafa Khasraw
Wenbin Li
2
+ Efficiencies of platform clinical trials: A vision of the future 2016 Benjamin R. Saville
Scott Berry
2
+ PDF Chat Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling 2016 Byron J. Gajewski
Scott Berry
William G. Barsan
Robert Silbergleit
William J. Meurer
Renee Martin
Gaylan L. Rockswold
2
+ Comparison of methods for control allocation in multiple arm studies using response adaptive randomization 2019 Kert Viele
Kristine Broglio
Anna McGlothlin
Benjamin R. Saville
2
+ Bayesian Adaptive Methods for Clinical Trials 2010 Scott Berry
Bradley P. Carlin
J. Jack Lee
Peter Müller
2
+ The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research 2015 Donald A. Berry
2
+ PDF Chat Outcome-Adaptive Randomization: Is It Useful? 2010 Edward L. Korn
Boris Freidlin
2
+ PDF Chat The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model 2016 Randall J. Bateman
Tammie L.S. Benzinger
Scott Berry
David B. Clifford
Cynthia Duggan
Anne M. Fagan
Kathleen Fanning
Martin R. Farlow
Jason Hassenstab
Eric McDade
2
+ Bayesian Hypothesis Testing in Two‐Arm Trials with Dichotomous Outcomes 2012 Boris G. Zaslavsky
2
+ PDF Chat Novel Methodologic Approaches to Phase I, II, and III Trials 2013 Sharon D. Yeatts
2
+ PDF Chat A Bayesian Credible Subgroups Approach to Identifying Patient Subgroups with Positive Treatment Effects 2016 Patrick Schnell
Qi Tang
Walter Offen
Bradley P. Carlin
2
+ PDF Chat Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both 2017 Janet Woodcock
Lisa M. LaVange
2
+ A group sequential, response-adaptive design for randomized clinical trials 2003 Theodore Karrison
Dezheng Huo
Rick Chappell
2
+ PDF Chat Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements 2017 Edward L. Korn
Boris Freidlin
2
+ PDF Chat Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols 2017 Mahesh Parmar
Matthew R. Sydes
Fay Cafferty
Babak Choodari‐Oskooei
Ruth E. Langley
Louise Brown
Patrick Phillips
Melissa Spears
Sam Rowley
Richard Kaplan
2
+ PDF Chat A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling 2019 Yong Zang
Beibei Guo
Yan Han
Sha Cao
Chi Zhang
2
+ PDF Chat Adaptive Clinical Trials: The Promise and the Caution 2010 Donald A. Berry
2
+ Bayesian clinical trials 2006 Donald A. Berry
2
+ PDF Chat Bayesian adaptive randomization designs for targeted agent development 2010 J. Jack Lee
Xuemin Gu
Suyu Liu
2
+ Optimal adaptive randomized designs for clinical trials 2007 Cheng Yi
Donald A. Berry
2
+ The Effect of Population Drift on Adaptively Randomized Trials 2007 John D. Cook
2
+ I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy 2009 AD Barker
C C Sigman
Kelloff Gj
NM Hylton
DA Berry
L. Esserman
2
+ Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials 2017 Richard Simon
2
+ Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection 2014 Kristine Broglio
Jason T. Connor
Scott Berry
2
+ Multiplicity Considerations in Clinical Trials 2018 Alex Dmitrienko
Ralph B. D’Agostino
2
+ A Multiple Comparison Procedure for Comparing Several Treatments with a Control 1955 Charles W. Dunnett
1
+ Optimality, Variability, Power 2003 Feifang Hu
William F. Rosenberger
1
+ Optimal Adaptive Designs for Binary Response Trials 2001 William F. Rosenberger
Nigel Stallard
Anastasia Ivanova
Cherice N. Harper
Michelle L. Ricks
1
+ Statistical Modeling of Clinical Trials (Recruitment and Randomization) 2011 Vladimir V. Anisimov
1
+ Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification 1986 John M. Lachin
Mary A. Foulkes
1
+ A Bayesian Group Sequential Approach to Safety Signal Detection 2013 Wenfeng Chen
Naiqing Zhao
Guoyou Qin
Jie Chen
1
+ Data Monitoring Committees In Clinical Trials: A Practical Perspective. Susan S. Ellenberg, Thomas R. Fleming and David L. DeMets, Wiley, Chichester, U.K., 2002. No. of pages: xiii+191. Price: £45.00. ISBN 0‐471‐48986‐7 2004 Diana Elbourne
1
+ Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials 2007 Björn Bornkamp
Frank Bretz
Alex Dmitrienko
Greg Enas
Brenda Gaydos
Chyi‐Hung Hsu
Franz König
Michael Krams
Qing Liu
Beat Neuenschwander
1
+ Modeling and prediction of subject accrual and event times in clinical trials: a systematic review 2012 Xiaoxi Zhang
Qi Long
1
+ PDF Chat The utility of Bayesian predictive probabilities for interim monitoring of clinical trials 2014 Benjamin R. Saville
Jason T. Connor
Gregory D. Ayers
JoAnn Alvarez
1
+ PDF Chat Prediction of accrual closure date in multi‐center clinical trials with discrete‐time Poisson process models 2012 Gong Tang
Yuanyuan Kong
Chung‐Chou Ho Chang
Lan Kong
Joseph P. Costantino
1
+ Predictive event modelling in multicenter clinical trials with waiting time to response 2011 Vladimir V. Anisimov
1
+ PDF Chat Multi-arm clinical trials with treatment selection: what can be gained and at what price? 2015 Thomas Jaki
1
+ Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas 2015 Ulrich Abel
Katrin Jensen
Irini Karapanagiotou‐Schenkel
Meinhard Kieser
1
+ PDF Chat An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project 2012 William J. Meurer
Roger J. Lewis
Danilo A. Tagle
Michael D. Fetters
Laurie Legocki
Scott Berry
Jason Connor
Valerie Durkalski
Jordan Elm
Wenle Zhao
1
+ The Platform Trial 2015 Scott Berry
Jason T. Connor
Roger Lewis
1
+ PDF Chat Dose Finding – A Challenge in Statistics 2008 Frank Bretz
Jason C. Hsu
José Paulo Pinheiro
Yi Liu
1
+ A Bayesian Inference of <i>P</i>(π<sub>1</sub> &gt; π<sub>2</sub>) for Two Proportions 2012 Youhei Kawasaki
Etsuo Miyaoka
1
+ Sample sizes for phase II and phase III clinical trials: An integrated approach 1986 John Whitehead
1
+ PDF Chat Frequentist Model Average Estimators 2003 Nils Lid Hjort
Gerda Claeskens
1
+ Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model 2004 Scott Berry
Donald A. Berry
1